Yahoo Web Search

Search results

    • Small Business - The Andalusia Star-News | The Andalusia Star-News

      The Andalusia Star-News· 2 hours ago

      NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology PR Newswire ROCKVILLE, Md., June 3, 2024 Results from study NIT-110 with NT-I7 and CPI combination treatment

    • L.A. Influential

      L.A. Influential

      Los Angeles Times· 1 day ago

      See who’s shaping Los Angeles’ major industries and cultural corners.

    • Small Business - Picayune Item | Picayune Item

      The Picayune Item· 2 days ago

      GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in ...

    • Small Business - Cordele Dispatch | Cordele Dispatch

      Cordele Dispatch· 1 day ago

      Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO PR Newswire BEIJING and SHANGHAI and CHICAGO, June 1, 2024 BEIJING and SHANGHAI and CHICAGO, June 1, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing